Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Pc4.0
Policosanol – Forschung
Hilft wahrscheinlich
104 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Policosanol scheint in 16 von 16 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1994–2025 mit einer typischen Studiengröße von 120 Teilnehmenden.
Basierend auf 104 Studien · 13 Meta-Analysen · 89 RCTs · 16,732 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
16geholfen· 88 weitere ohne bewertete Effektdaten
Nach Outcome
Cholesterol & lipidsLipidvorteile in kubanischen Studien beobachtet, aber von unabhängigen RCTs nicht reproduziert · 6-8 Wochen
Hilft wahrscheinlich76 Studien
Heart & blood pressureLipidvorteile in kubanischen Studien beobachtet, aber von unabhängigen RCTs nicht reproduziert · 6-8 Wochen
Hilft wahrscheinlich33 Studien
Glucose & metabolic
Hilft wahrscheinlich7 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Liver health
Überwiegend Mechanismus / Beobachtung3 Studien
Cognitive function
Überwiegend Mechanismus / Beobachtung3 Studien
Weight management
Zu wenige bewertete Studien2 Studien
In Zahlen
Aus 29 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
92%
über Studien hinweg
Untersuchte Personen
17k
typische Studie: 120 Personen
Stärkste Designs
102
13 gepoolt, 89 randomisiert
Zeigte Nutzen
100%
16/16 Studien
Wie lange Studien liefen
1–3 Monate
11
3+ Monate
4
Untersuchte Populationen
Adults2
Patients with hyperlipidemia2
Hypercholesterolemic patients2
Adults with blood glucose concerns1
Stetige Forschung
14 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
199420092025
1Blood glucose levelsMeta-AnalyseCited 10×n=2,680 · very large study2024
To assess the effects of policosanol on glucose, we employed a random-effects or fixed-effects meta-analysis approach to examine the weighted mean differences (WMDs) and associated 95 % confidence ...
Reza Amini M et al. · Diabetes research and clinical practice (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
To assess the effects of policosanol on glucose, we employed a random-effects or fixed-effects meta-analysis approach to examine the weighted mean differences (WMDs) and associated 95 % confidence intervals (CI) before and after policosanol and placebo administration.
Compared to the control group, policosanol supplementation significantly reduced blood glucose levels (WMD: -2.24 mg/dl; 95 % CI: -4.05, -0.42, P = 0.01).
Findings from subgroup analysis revealed a significant reduction of policosanol supplementation on glucose levels in period of less than 24 weeks, and in individuals below 50 years of age.
2Liver enzymes (ALT and AST)Meta-AnalyseCited 3×n=2,535 · very large study2024
Policosanol supplementation exerts a beneficial effect on liver enzymes as well as ALT and AST concentrations in adults.
Gholamrezayi A et al. · Complementary therapies in medicine (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
The combination of effect sizes, regarding the random-effects model, demonstrated significant changes in ALT serum levels after intervention (WMD: -1.48 U/L; 95% CI: -2.33 to -0.64; P = 0.001), and AST (WMD: -1.10 U/L; 95% CI: -1.70 to -0.51; P < 0.001).
Policosanol supplementation exerts a beneficial effect on liver enzymes as well as ALT and AST concentrations in adults.
However, further long-term and well-designed RCTs with better quality are needed to further assess and confirm these results.
3LDL-C levelsSystematische ÜbersichtCited 13×n=837 · large study2021
This systemic review shows that the apparent lack of effectiveness of diet manipulation in modulating plasma levels of LDL-C among individuals with HeFH is likely due to biases in study designs, rather than a true lack of effects.
Roy G et al. · Nutrients (2021)
A significant reduction in LDL-C levels was reported in 10 RCTs, including eight dietary supplement interventions (phytosterols, n = 6, omega-3, n = 1; guar gum, n = 1), one food-based intervention and one dietary counseling intervention.
Studies at low risk of biases were more likely to report significant reductions in LDL-C concentrations, compared with studies at risk of bias (chi-square statistic: 5.49; p = 0.02).
This systemic review shows that the apparent lack of effectiveness of diet manipulation in modulating plasma levels of LDL-C among individuals with HeFH is likely due to biases in study designs, rather than a true lack of effects.
4Lipid levelsMeta-AnalyseCited 45×n=1,886 · large study2018
The pooled results supported the lipid-lowering effects and safety of policosanol.
Gong J et al. · Molecular nutrition & food research (2018)
The pooled results supported the lipid-lowering effects and safety of policosanol.
Because of the high heterogeneity, the better treatment effects observed in the Cuban studies and the inconsistent dose-response relationship, more clinical trials are needed to further confirm the efficacy of policosanol on dyslipidemia.
5Plasma lipid and glucose levelsMeta-AnalyseCited 80×n=1,670 · large study2016
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Pirro M et al. · Pharmacological research (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Overall, WMDs were significant for the impact of NComb supplementation on plasma levels of total cholesterol (-26.15mg/dL, p<0.001), LDL-cholesterol (-23.85mg/dL, p<0.001), HDL-cholesterol (2.53mg/dL, p<0.001), triglycerides (-13.83mg/dL, p<0.001) and glucose (-2.59mg/dL, p=0.010).
NComb-induced amelioration of lipid profile was not affected by duration of supplementation nor by baseline lipid levels; conversely, a greater glucose-lowering effect of NComb was found with higher baseline glucose levels and longer durations of supplementation.
12LDL cholesterol reductionMeta-AnalyseCited 72×n=4,596 · very large study2005
Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.
Chen JT et al. · Pharmacotherapy (2005)
Groß Nutzen
← SchlechterKein EffektBesser →
Likely real
The net LDL reduction in the treatment groups minus that in the placebo groups was greater with policosanol than plant sterols and stanols (-24% versus -10%, p<0.0001).
Policosanol caused a clinically significant decrease in the LDL:HDL ratio.
Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
Millán J et al. · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (2016)
Kaum spürbar Nutzen
← SchlechterKein EffektBesser →
The effect size (relative change from baseline (%)) was -1.3 (9.9%) for total cholesterol, -1.17 (-13.7%) for LDL-c, +0.17 (+3.7%) for HDL-c and -0.24 (-7.0%) for Triglycerides.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
16Systolic and diastolic blood pressureRCTCited 1×n=200 · medium study2025
It is concluded that policosanol 20 mg/day given for 12 weeks to Cuban patients with prehypertension lowered SBP and DBP and produced beneficial changes in the lipid profile, being well tolerated.
Revueltas M et al. · Journal of clinical hypertension (Greenwich, Conn.) (2025)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Also, more (p < 0.0001) policosanol patients (44%) reached SBP reductions ≥10 mmHg and DBP reductions ≥5 mmHg versus baseline (44% and 61%, respectively) than placebo patients (7% and 22%, respectively).
Nine patients (4.5%) discontinued the trial, none because of AE.
Four patients (3 placebo, 1 policosanol) reported AE.
17Systolic blood pressureRCTn=200 · medium study2025
It is concluded that oral administration of policosanol 20 mg/day for twelve weeks significantly lowered SBP and DBP in Cuban patients with grade I hypertension, and improved lipid profile variables, being safe and well tolerated.
Revueltas Aguero M et al. · Journal of clinical hypertension (Greenwich, Conn.) (2025)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
At study completion, policosanol significantly lowered (p < 0.001) SBP, the primary outcome, by more than 10 mmHg related to baseline and placebo, while also significantly decreasing (p < 0.001) DBP values versus baseline and placebo.
Also, more (p < 0.001) policosanol patients reached SBP reductions ≥10 mmHg and DBP reductions ≥5 mmHg versus baseline (74% and 91%, respectively) than placebo patients (12% and 15%, respectively).
Policosanol significantly lowered low-density lipoprotein-cholesterol (LDL-C) and total cholesterol, while increasing high-density lipoprotein-cholesterol (HDL-C).
18Left ventricular mass reductionRCTCited 18×n=158 · medium study2020
24-week of treatment with AP is associated with a significant reduction in LVM in subjects with MS and LVH, in addition to favourable effects on lipid profile, and could represent an effective strategy aiming at reducing the associated cardiovascular risk.
Mercurio V et al. · Clinical nutrition (Edinburgh, Scotland) (2020)
Kaum spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
A significant percentage reduction in LVM was observed in AP group vs baseline (-2.7%, p < 0.0001), and compared to placebo (-4.1%, p < 0.0001), and remained significant after adjustment for age, sex, baseline systolic BP and BMI and their changes during the study period.
The proportion of subjects showing LVM reduction was higher in AP group than in the placebo group (57% vs 28%, adjusted p = 0.007).
24-week of treatment with AP is associated with a significant reduction in LVM in subjects with MS and LVH, in addition to favourable effects on lipid profile, and could represent an effective strategy aiming at reducing the associated cardiovascular risk.
The results of this study, applicable to a specific local population show that, in a population of subjects affected by MetS, treatment with AP improves the lipid profile and the most atherogenic factors, thus suggesting a reduction in the risk of development and progression of atherosclerosis, particularly in subjects with high atherogenic risk, due to the presence of sdLDL-C.
Galletti F et al. · Lipids in health and disease (2019)